ImmunityBio, Inc.
The research page contains a warning that has not been mapped to a supported model interpretation. The company research remains available, but the complete score is withheld until the warning is reviewed.
IBRX · Price history
Price at last available close
$8.83
+$0.31 (+3.64%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About ImmunityBio, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms.
How they make money
ImmunityBio is a vertically integrated biotechnology company that generates revenue primarily through the commercial sale of its immunotherapy product, ANKTIVA. The company utilizes its proprietary Cancer BioShield platform to develop and market therapies that activate the natural immune system to combat cancers and infectious diseases.
Products & services
The company's primary commercial product is ANKTIVA (nogapendekin alfa inbakicept-pmln), an IL-15 superagonist immunotherapy used in combination with other therapies for the treatment of various cancers.
Brands & revenue mix
IL-15 superagonist immunotherapy for cancer treatment.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Geographic revenue
Customer types
- Hospitals and oncology clinicsSource
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical and commercial drug supply.Source
Strengths
Company-specific research
Questions worth answering for IBRX
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can IBRX maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can IBRX fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Is IBRX's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for IBRX to reach sustainable profitability?
- •What future growth or profitability would be needed to justify IBRX's current valuation?
Essential Investment Snapshot
Market Cap
$9.36B
P/E Ratio
-9.7
EPS
$-0.97
52-Week High
$12.43
52-Week Low
$1.95
Beta
0.14
Analyst Target
$12.00
Shares Outstanding
919.9M
Total Debt
$813.1M
Dividend
No current dividend
Liquidation Value / Share
$-1.14
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
High movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for IBRX
Detected from reported data — verify before acting.Severe debt stress
Negative shareholder equity • Total debt is at least one year of revenue • Interest coverage is below 2x • Free cash flow is negative • Cash covers less than 20% of total debt
M&A headline · Sep 2, 2026
Canada Pension Plan Investment Board Acquires Shares of 70,200 ImmunityBio, Inc. $IBRX — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Defense WorldCommunity Sentiment
0 active · 0 total callsNo personal call yet on IBRX.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Vertically integrated manufacturing capabilities.
- +Proprietary Cancer BioShield platform.
Potential downside factors
- −Debt risk (severe): Negative shareholder equity.
- −Total debt is at least one year of revenue.
- −Interest coverage is below 2x.
- −Free cash flow is negative.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$8.83
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: +668.3%
Revenue changed sharply from 2024 to 2025. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $165.8M | $113.3M | $14.7M | $622K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $1.1M | $753K | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $164.7M | $112.5M | $14.7M | $622K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $226.9M | $207.9M | $190.1M | $232.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $167.3M | $147.2M | $168.8M | $129.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $416.5M | $368.6M | $358.9M | $362.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$888.3M | -$223.6M | -$264.4M | -$478.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$251.8M | -$256.0M | -$344.2M | -$362.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $83.3M | $112.5M | $131.7M | $86.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$992.6M | -$351.6M | -$413.6M | -$583.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | -$179K | -$135K | $0.00 | -$40K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$992.4M | -$351.4M | -$413.6M | -$583.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-0.97 | $-0.38 | $-0.59 | $-1.15 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 1.05B | 920M | 697M | 509M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 1.05B | 920M | 700M | 509M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$51.2M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.22
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+51.9%
Cash Change
-45.0%
Margin Change
-99.4 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Weakened
- Margins contracted
- Cash position declined
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, EPS growth. Pressure indicators included cash levels, debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 93.9%. EPS increased 120.0%. Cash declined 45.0%. Total debt increased 51.9%. Net income margin declined by 99.4 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer
ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment
ImmunityBio Stock Climbs Thursday: What's Going On?
ImmunityBio (NASDAQ:IBRX) vs. Monte Rosa Therapeutics (NASDAQ:GLUE) Financial Survey
Rumor Mill · IBRX
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial